AVIR — Atea Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$5.61
+$0.12 (+2.19%)
Atea Pharmaceuticals Inc (AVIR) is a biotechnology company listed on NASDAQ. It is led by Jean-Pierre Sommadossi Ph.D., based in 225 Franklin Street, Boston, MA, United States, 02110, with about 55 employees. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Net income was -$113.5M. AVIR currently screens at market cap $353.7M.
Use this AVIR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AVIR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AVIR SEC filings page. Lician reads the product cache first so this HTML stays unique to Atea Pharmaceuticals Inc even when a live quote feed is slow.
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Key Statistics
Market Cap
$353.72M
Volume
69,845
Previous Close
$5.51
Day Range
$5.46 – $5.62
EPS
-$2.00
Revenue
$0.00
Net Income
-$168.38M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
55
AVIR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $351.37M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$168.38M | -$135.96M | -$115.91M | $121.19M |
| EPS (Diluted) | -$2.00 | -$1.63 | -$1.39 | $1.37 |
Total Assets
$464.67M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$64.70M
Operating Cash Flow
-$135.50M
Free Cash Flow
$0.00
Atea Pharmaceuticals Inc Company Information
- Founder, Chairman, CEO & President
- Jean-Pierre Sommadossi Ph.D.
- Headquarters
- 225 Franklin Street, Boston, MA, United States, 02110
- Website
- ateapharma.com
- Phone
- 857 284 8891
- IPO / Founded
- 2020-10-30
- Sector
- Healthcare
- Industry
- Biotechnology